151 related articles for article (PubMed ID: 35681071)
1. Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing.
Teranishi Y; Miyawaki S; Nakatomi H; Ohara K; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Morishita S; Tsuji S; Saito N
Sci Rep; 2022 Jun; 12(1):9543. PubMed ID: 35681071
[TBL] [Abstract][Full Text] [Related]
2. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
[TBL] [Abstract][Full Text] [Related]
3. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
4. Origins of biallelic inactivation of NF2 in neurofibromatosis type 2.
Xue L; He W; Zhang Y; Wang Z; Chen H; Chen Z; Zhu W; Liu D; Jia H; Jiang Y; Wang Z; Wu H
Neuro Oncol; 2022 Jun; 24(6):903-913. PubMed ID: 34918118
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A; Jones A; Joe H; Heap L; Smith MJ; Wallace AJ; Halliday D; Parry A; Taylor A; Raymond L; Shaw A; Afridi S; Obholzer R; Axon P; King AT; ; Friedman JM; Evans DG
J Med Genet; 2015 Oct; 52(10):699-705. PubMed ID: 26275417
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
8. Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity.
Halliday D; Emmanouil B; Vassallo G; Lascelles K; Nicholson J; Chandratre S; Anand G; Wasik M; Pretorius P; Evans DG; Parry A;
Clin Genet; 2019 Aug; 96(2):151-162. PubMed ID: 30993672
[TBL] [Abstract][Full Text] [Related]
9. [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L; De Moncuit C; Thomas G; Olschwang S
Rev Neurol (Paris); 2007 Nov; 163(11):1031-8. PubMed ID: 18033041
[TBL] [Abstract][Full Text] [Related]
10. In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2: From Genotype to Phenotype.
Heineman TE; Evans DG; Campagne F; Selesnick SH
Otol Neurotol; 2015 Jun; 36(5):908-14. PubMed ID: 25931164
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component.
Catasús N; Garcia B; Galván-Femenía I; Plana A; Negro A; Rosas I; Ros A; Amilibia E; Becerra JL; Hostalot C; Rocaribas F; Bielsa I; Lazaro Garcia C; de Cid R; Serra E; Blanco I; Castellanos E;
J Med Genet; 2022 Jul; 59(7):678-686. PubMed ID: 34348961
[TBL] [Abstract][Full Text] [Related]
12. Correlation between genotype and phenotype with special attention to hearing in 14 Japanese cases of NF2-related schwannomatosis.
Oishi N; Noguchi M; Fujioka M; Nara K; Wasano K; Mutai H; Kawakita R; Tamura R; Karatsu K; Morimoto Y; Toda M; Ozawa H; Matsunaga T
Sci Rep; 2023 Apr; 13(1):6595. PubMed ID: 37087513
[TBL] [Abstract][Full Text] [Related]
13. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
14. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.
Evans DG; Trueman L; Wallace A; Collins S; Strachan T
J Med Genet; 1998 Jun; 35(6):450-5. PubMed ID: 9643284
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis type 2 and related disorders.
Halliday D; Parry A; Evans DG
Curr Opin Oncol; 2019 Nov; 31(6):562-567. PubMed ID: 31425178
[TBL] [Abstract][Full Text] [Related]
16. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
18. Further genotype--phenotype correlations in neurofibromatosis 2.
Selvanathan SK; Shenton A; Ferner R; Wallace AJ; Huson SM; Ramsden RT; Evans DG
Clin Genet; 2010 Feb; 77(2):163-70. PubMed ID: 19968670
[TBL] [Abstract][Full Text] [Related]
19. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.
Emmanouil B; Houston R; May A; Ramsden JD; Hanemann CO; Halliday D; Parry A; Mackeith S
Laryngoscope; 2019 Apr; 129(4):974-980. PubMed ID: 30456886
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients.
Aboukais R; Baroncini M; Zairi F; Bonne NX; Schapira S; Vincent C; Lejeune JP
Acta Neurochir (Wien); 2013 May; 155(5):771-7. PubMed ID: 23381342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
